Evidence map›Paper›PMID 40087231›Full record

ArticleDermatology and therapy2025

Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study.

Stephan Weidinger, Tobias Schadeck, Felix Jacobs, Ansgar Weyergraf, Dariusch Mortazawi, Tobias Hagemann, Fatima Abousamra, Thomas Mosch, Bjoern Fritz, Felix Lauffer

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05139836 (Non-Interventional, Prospective Observational Cohort Study to Investigate the Effectiveness and Sustained Disease Control of an Upadacitinib Therapy in Moderate to Severe Atopic Dermatitis Patients Over Two Years), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05139836 active not recruitingnot on this map

Non-Interventional, Prospective Observational Cohort Study to Investigate the Effectiveness and Sustained Disease Control of an Upadacitinib Therapy in Moderate to Severe Atopic Dermatitis Patients Over Two Years

TypeobservationalSponsorAbbVieRan2021 to 2027Enrolled634ConditionsAtopic Dermatitis
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephan WeidingerDepartment of Dermatology and Allergy, University Hospital Schleswig-Holstein, Rosalind-Franklin-Straße 7, 24105, Kiel, Germany. sweidinger@dermatology.uni-kiel.de.ORCID http://orcid.org/0000-0003-3944-252X
Tobias SchadeckDermatology Practice, Bogen, Germany.
Felix JacobsDermatology Practice Dr. Jacobs & Colleagues, Kulmbach, Germany.
Ansgar WeyergrafDermatology Practice, Bramsche, Germany.
Dariusch MortazawiDermatology Practice, Remscheid, Germany.
Tobias HagemannDermatology Practice, Lippstadt, Germany.
Fatima AbousamraAbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
Thomas MoschAbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
Bjoern FritzAbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
Felix LaufferDepartment of Dermatology, Ludwig-Maximilians University Hospital, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPhase 3 clinical trials have demonstrated robust efficacy and favorable safety of upadacitinib for the treatment of atopic dermatitis (AD). However, real-world data are still sparse. The objectives of this study were to assess the effectiveness and safety of real-world treatment with upadacitinib in patients with moderate-to-severe AD.

methodsUP-TAINED is an ongoing German prospective, multicenter, observational study in adolescents and adults with moderate-to-severe AD treated with upadacitinib 15 or 30 mg once daily, according to local labeling. Effectiveness (primary endpoint; measured with the Atopic Dermatitis Control Tool [ADCT]) and safety are assessed over 2 years. Reported here are 1-year results from an interim analysis.

resultsData on 351 patients were included in the effectiveness analysis. At 12 weeks, 71.0% of patients had achieved disease control (ADCT total score < 7); at 1 year, this rate was 70.9%. An Eczema Area and Severity Index (EASI) ≤ 3 was achieved by 60.6% of patients after 4 weeks and 68.1% after 1 year of upadacitinib treatment. Of 186 patients with moderate-to-severe facial eczema at baseline and 142 patients with moderate-to-severe hand eczema at baseline, 60.8% (101/166) and 63.8% (83/101) achieved clear or almost clear skin in those respective body regions after 4 weeks of upadacitinib treatment. Of the 380 patients included in the safety analysis, 163 patients reported 426 adverse events (AEs), most classified as mild (59.7%) or moderate (34.6%). The most common AEs were (worsening of) AD, acne, and COVID-19. No major cardiovascular AEs, venous thromboembolism, or malignancies were reported.

conclusionsUpadacitinib was well tolerated, and the majority of patients with moderate-to- severe AD receiving upadacitinib in real-world clinical practice achieved stringent treatment goals with early and up to 1-year disease control attained, particularly in difficult-to-treat areas such as hand and face. CLINICAL

trial registrationClinicalTrials.gov, NCT05139836.

Indexed as

Atopic dermatitisDisease controlEczemaGermanyReal-world treatmentUpadacitinib

Identifiers

PMID40087231
PMCPMC11971103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.